Who owns Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. and Intuitive Surgical-Fosun (HongKong) Co., Ltd. (the "Joint Venture", with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. and Intuitive Surgical-Fosun (HongKong) Co., Ltd. (the "Joint Venture", with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.) - Profile

The Intuitive Fosun joint venture researches, develops, manufactures and sells robotic assisted, catheter based medical devices, starting with tools for the early diagnosis and cost effective treatment of lung cancer. Announced in September 2016, it pairs Intuitive Surgical's robotics and flexible catheter engineering with Shanghai Fosun Pharmaceutical's Chinese regulatory, manufacturing and commercial reach, and runs its research, development and manufacturing from Shanghai through a mainland operating company with a Hong Kong entity alongside it. The venture handles distribution inside China while Intuitive distributes the products elsewhere, and the partners agreed to contribute up to $100 million between them as the business requires it. It builds on a relationship that began in 2011, when Fosun's Chindex Medical became a distributor of da Vinci surgical systems in China.

The disclosed stakes

One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.

Where each figure comes from

A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.

• Intuitive Surgical, Inc.. Percentage is a filed fact: FY2025 10-K states the Joint Venture is owned 60 percent by Intuitive Surgical and 40 percent by Fosun Pharma. No dollar value is disclosed for Intuitive's 60 percent interest specifically; only Fosun Pharma's 40 percent noncontrolling interest is carried on Intuitive's consolidated balance sheet, at $129.3 million as of 30 June 2026 and $117.7 million as of 31 December 2025. If the noncontrolling interest is proportional to Fosun's 40 percent, total Joint Venture equity would be roughly $323 million as of 30 June 2026 and Intuitive's 60 percent share roughly $194 million, but this is an inference from the balance sheet split, not a disclosed figure, so it is not entered as value_usd. sourcesource 2